Ignite Creation Date:
2025-12-24 @ 5:24 PM
Ignite Modification Date:
2025-12-28 @ 8:13 PM
Study NCT ID:
NCT01168050
Status:
UNKNOWN
Last Update Posted:
2011-02-08
First Post:
2010-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
P081237
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Zakia Idir
Old Organization:
Department Clinical Research of Developpement